Bottom line
HRTS vs RYHIX: the short answer
HRTS (Tema Heart & Health ETF) and RYHIX (Health Care Fund) are both etfs.
But RYHIX is far broader, holding 135 positions to 45 for HRTS, so beyond the top names it adds exposure HRTS doesn't have.
HRTS is cheaper at 0.75% vs 1.38% — a difference of $63 a year per $10,000 invested.
Over one year, HRTS returned +23.6% vs +14.4% for RYHIX.
Updated Nov 19, 2026
HRTS vs RYHIX side by side
| HRTS | RYHIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Innovator | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.75% | 1.38% |
| Annual cost per $10k | $75 | $138 |
| 10-yr cost on $10k (prospectus) | $1,168 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +23.6% | +14.4% |
| 5-yr return (annualized) | — | +5.1% |
| 10-yr return (annualized) | — | +7.9% |
| Best quarter | +15.8% | +18.7% |
| Worst quarter | −12.4% | −14.4% |
| Net assets (fund) | $51.9M | $19.4M |
| Number of holdings | 45 | 135 |
| Portfolio turnover | 4% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | HRTS | RYHIX | Difference |
|---|---|---|---|
| 2025 | +23.6% | +14.4% | +9.2% |
| 2024 | +3.6% | +0.6% | +3.0% |
Source: Fund prospectus bar charts
Holdings overlap
15 of HRTS's top 25 holdings also appear in RYHIX's top 25.
| Holding | HRTS | RYHIX |
|---|---|---|
| Eli Lilly & Co | 11.52% | 3.63% |
| UnitedHealth Group Inc | 5.24% | 2.22% |
| Merck & Co Inc | 4.27% | 2.04% |
| Thermo Fisher Scientific Inc | 3.97% | 1.61% |
| Johnson & Johnson | 3.59% | 2.88% |
| Gilead Sciences Inc | 3.43% | 1.39% |
| Vertex Pharmaceuticals Inc | 2.93% | 1.34% |
| Danaher Corp | 2.66% | 1.30% |
| Abbott Laboratories | 2.61% | 1.42% |
| AbbVie Inc | 2.40% | 2.52% |
| Bristol-Myers Squibb Co | 2.09% | 1.22% |
| Amgen Inc | 1.91% | 1.56% |
| Edwards Lifesciences Corp | 1.75% | 0.84% |
| McKesson Corp | 1.71% | 1.05% |
| Regeneron Pharmaceuticals Inc | 1.67% | 0.90% |
Source: SEC Form N-PORT
HRTS top 10
- Eli Lilly & Co — 11.52%
- UnitedHealth Group Inc — 5.24%
- Novo Nordisk A/S — 5.24%
- Roche Holding AG — 4.50%
- Merck & Co Inc — 4.27%
- AstraZeneca PLC — 4.00%
- Thermo Fisher Scientific Inc — 3.97%
- Johnson & Johnson — 3.59%
- Gilead Sciences Inc — 3.43%
- Novartis AG — 3.38%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between HRTS and RYHIX?
Which is cheaper, HRTS or RYHIX?
Should I own both HRTS and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.